Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: A pre-clinical study

International Journal of Cancer

Volumn 80, Issue 4, 1999, Pages 612-616

  Pfosser, Achim ^a   Brandl, Martina ^a,b   Salih, Helmut ^a   Grosse Hovest, Ludger ^a,b   Jung, Gundram ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEOCHONDROITIN SULFATE; T LYMPHOCYTE RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CELL SURFACE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; GLIOBLASTOMA; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICROSCOPY, FLUORESCENCE; PROTEOCHONDROITIN SULFATES; RECEPTOR, EPIDERMAL GROWTH FACTOR; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0033521879     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990209)80:4<612::AID-IJC21>3.0.CO;2-K     Document Type: Article

References (19)

1. BINDON, C.I., HALE, G. and WALDMAN, H., Importance of antigen specificity for complement mediated lysis by monoclonal antibodies. Europ. J. Immunol., 18, 1507-1514 (1988).
2. BOHLEN, H., MANZKE, O., PATEL, B., DÖRKEN, B., VON FLIEDNER, V., DIEHL, V. and TESCH, H., Cytolysis of leukemic B cells by T cells activated via two bispecific antibodies. Cancer Res., 53, 4310-4314 (1993).
3. BOHLEN, H., MANZKE, O., TITZER, S., LORENZEN, J., KUBE, D., ENGERT, A., ABKEN, H., WOLF, J., DIEHL, V. and TESCH, H., Prevention of Epstein-Barr virus induced human B-cell lymphoma in severe-combined immunodeficient mice treated with CDI9 X CD3 bispecific antibodies, CD28 monospecific antibodies and autologous T cells. Cancer Res., 57, 1704-1709 (1997).
4. CHERESH, D.A., HONSIK, C.J., STAFFILENO, L.K., JUNG, G. and REISFELD, R.A., Disialoganglioside GD3 on human melanoma cells serves as a relevant target antigen for monoclonal antibody-mediated tumor cell lysis. Proc. nat. Acad. Sci. (Wash.), 82, 5155-5159 (1985).
5. CHRISTIAANSEN, J.E. and SEARS, D.W., Unusually efficient tumor-cell lysis by human effectors of antibody dependent cellular cytotoxicity mediated by monoclonal antibodies. Cancer Res., 44, 3712-3718 (1984).
6. GUO, Y.J., CHE, X.Y., SHEN, F. TIAN-PEI, X., MA, J., WANG, X.N., WU, S.G., ANTHONY, D.D. and WU, M.C., Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nature Med., 3, 451-455 (1997).
7. HARPER, J.R. and REISFELD, R.A., Cell-associated proteoglycans in human malignant melanoma. In: T.N. Wight and R.P. Mecham (eds.). Biology of proteoglycans, pp. 345-364. Academic Press, San Diego (1987).
8. JUNG, G., FREIMANN, U., MARSCHALL, Z., REISFELD, R.A. and WILMANNS, W., Target cell induced T-cell activation with bi- and trispecific antibody fragments. Europ. J. Immunol., 21, 2431-2435 (1991).
9. JUNG, G., MARTIN, D.E. and MÜLLER-EBERHARD, H.J., Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. J. Immunol., 139, 639-644 (1987).
10. JUNG, G. and MÜLLER-EBERHARD, H.J., An in vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol. Today, 9, 257-260 (1988).
11. KROESEN, B.-J., BAKKER, A., VAN LIER, R.A., THE, H.T. and DE LEU, L., Bispecific antibody mediatred target cell specific costimulation of resting T cells via CD5 and CD28. Cancer Res., 55, 4409-4415 (1995).
12. LEDBETTER, J.A., JUNE, C.H., MARTIN, P.J., SPOONER, C.E., HANSEN, J.A. and MEIER, K.E., Valency of CD3 binding and internalization of the CD3 cell-surface complex control T-cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium and proliferation. J. Immunol., 136, 3945-3952 (1986).
13. LINSLEY, A. and LEDBETTER, J.A., The role of the CD28 receptor during T-cell responses to antigen. Ann. Rev. Immunol., 11, 191-212 (1993).
14. MACK, M., GRUBER, R., SCHMIDT, S., RIETHMÜLLER, R. and KUFER, P., Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3. J. Immunol., 158, 3965-3970 (1997).
15. MATZINGER, P., Tolerance, danger and the extended family. Ann. Rev. Immunol., 12, 991-1045 (1994).
16. MATZKU, S., BRÖCKER, E.-B., BRÜGGEN, J., DIPPOLD, W.G. and TILGEN, W., Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res., 46, 3848-3854 (1986).
17. MAZZONI, A., MEZZANZANICA, D., JUNG, G., WOLF, H., COLNAGHI, M. and CANEVARI, S., Preclinical evaluation of CD3-CD28 costimulation as a means to avoid T-cell preactivation in bispecitic-monoclonal-amibody-based treatment of ovarian carcinoma. Cancer Res., 56, 5443-5449 (1996).
18. SCHRAPPE, M., KLIER, F.G., SPIRO, R.C., WALTZ, T.A., REISFELD, R.A. and GLADSON, C.L., Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astriglial cells. Cancer Res., 51, 4986-4993 (1991).
19. WILLIAMS, J.M., DELORIA, D., HANSEN, J.A., DINARELLO, C.A., LOERTSCHER, R., SHAPIRO, H.M. and STROM, T.B., The events of primary T-cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin-1. J. Immunol., 135, 2249-2255 (1985).